Compare Akamai Technologies, Inc. (AKAM) vs Sanofi SA (SNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Akamai Technologies, Inc. vs Sanofi SA — how do they compare? Akamai Technologies, Inc. trades at $122.85 (market cap $16.63B), while Sanofi SA trades at $43.05 (market cap $103.29B). The key difference: Sanofi SA is far larger — about 6.2× Akamai Technologies, Inc.'s market cap, and Sanofi SA pays a 5.63% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | SNY | |
|---|---|---|
Market Cap | $16.63B | $103.29B |
Sector | Technology | Health |
52-Week High | $161.14 | $52.34 |
52-Week Low | $70.53 | $41.33 |
Enterprise Value | $21.56B | $119.78B |
Dividend Yield | — | 5.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $114.37, up 1.06% on the day but down significantly from its 26-year high of $165.45 in May 2026. The stock faces a bearish technical signal despite recent earnings beats. Revenue growth has slowed to 5% annually, with net income margin declining from 14.47% in 2022 to 10.74% in 2025. The company continues strategic moves in cybersecurity, completing the LayerX acquisition and expanding its NVIDIA partnership for AI security.
While analyst consensus remains positive with a $170.20 price target, near-term headwinds include declining profitability, high valuation multiples, and competitive pressures. The stock's current pullback presents a potential entry point for long-term investors believing in its cybersecurity and cloud computing positioning, though execution risks and margin compression require monitoring.
SNY trades at $42.98, down 0.42% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q1 2026 results with EPS of $1.10 beating expectations of $1.06, continuing a trend of positive surprises. Revenue grew to $46.72 billion in 2025 with net income margin improving to 16.72%. Recent developments include EU approval for Cenrifki in multiple sclerosis and FDA approval for Tzield expansion in pediatric diabetes treatment.
SNY presents a mixed investment case with solid fundamentals offset by technical weakness. The stock trades at reasonable valuations (P/E 18.9, P/S 1.92) with strong profitability metrics, but faces near-term headwinds from an antitrust probe and bearish technical indicators. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism amid regulatory uncertainties and pipeline execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
